BRIEF-Bristol-Myers Squibb Co Says New Five-Year Sotyktu (Deucravacitinib) Data Show Consistent Safety And Durable Response Rates In Moderate-To-Severe Plaque Psoriasis

Reuters
16 Feb
BRIEF-Bristol-Myers Squibb Co Says New Five-Year Sotyktu (Deucravacitinib) Data Show Consistent Safety And Durable Response Rates In Moderate-To-Severe Plaque Psoriasis

Feb 16 (Reuters) - Bristol-Myers Squibb Co BMY.N:

  • BRISTOL-MYERS SQUIBB CO - NEW FIVE-YEAR SOTYKTU (DEUCRAVACITINIB) DATA SHOW CONSISTENT SAFETY AND DURABLE RESPONSE RATES IN MODERATE-TO-SEVERE PLAQUE PSORIASIS

Source text: ID:nBw89WLb6a

Further company coverage: BMY.N

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10